In Brief: Ela Medical
This article was originally published in The Gray Sheet
Executive Summary
Ela Medical: Montrouge, France-based subsidiary of Synthelabo's Biomedical division commences European roll-out of ventricular models of its Stelid family of steroid-eluding pacing leads. The devices incorporate a steroid collar technology that allows for release during the initial days after implantation of the anti-inflammatory drug dexamethasone, and a micro porous carbon electrode. Atrial models of the Stelid devices are undergoing clinical evaluation and are slated for European launch by the end of the year. Separately, Ela reports the European introduction of its Defender II 75 cc dual-chamber defibrillator. The device features the company's Parad algorithm, which allows for collection of both atrial and ventricular data...